US To Purchase 600K Additional Doses of GSK-Vir's COVID-19 Antibody Therapy

The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc GSK and Vir Biotechnology Inc's VIR COVID-19 antibody therapy for an undisclosed sum.

  • The companies would supply the additional doses of sotrovimab to the U.S. in Q1 of 2022, taking the tally of doses secured by nations worldwide to roughly 1.7 million.
  • The U.S. government in November had signed contracts worth about $1 billion for an unknown number of doses of the treatment after saying it would control the distribution of sotrovimab.
  • Related: Glaxo-Vir Biotech's Antibody Approved In Europe For Early Treatment Of COVID-19.
  • GSK and Vir said they expect to produce roughly 2 million doses of sotrovimab globally in 1H of 2022.
  • Price Action: VIR stock is down 0.42% at $33.28, while GSK shares are up 0.28% at $44.97 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechGovernmentLong IdeasNewsHealth CareContractsTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!